Leadership Message

Today, cancers and autoimmune diseases still remain a major threat to human health and life worldwide. China is taking an increasingly critical role joining the global fight for the prosperity of human health. Currently China has more than 30 million patients with autoimmune diseases and accounts for over 50% of all liver cancer patients as well as over 25% of patients suffering from lung, gastric, and other cancers globally. The ever-increasing incidence rates and the lack of effective treatments have significantly diminished the survival rates and the quality of life for these individuals. InnoCare is committed to developing safe and effective novel treatments to address these urgent and unmet medical needs.

InnoCare has a world-class R&D team and an extraordinary scientific advisory board (SAB). Our R&D team members have extensive experience in new drug R&D with renowned biomedical companies and have successfully developed hundreds of new drug candidates and products. The InnoCare SAB members are comprised of bioscience leaders from elite universities, medical experts from top domestic hospitals and distinguished researchers from global pharmaceutical companies. Together, they will guide the company to remain at the forefront of international drug R&D technology. Our R&D team and SAB members comprises InnoCare’s core. They are passionate, rigorous, pragmatic, and committed to using the latest scientific discovery and technologies to drive new drug R&D with the ultimate goal to provide patients, globally, with the finest, novel medicines.

At InnoCare, we encourage innovation and creative thinking. We have adopted an open and organized R&D system with the concepts of clear and transparent communication, timely and effective execution, as well as flexible and rapid action. We believe that “common goals, mutual trust, and cooperation” will unify and strengthen our team. These principles constitute the key foundation to the competitiveness of our company and the essential elements to ensure our success in becoming a global leader in the biomedical industry.